CATALOGO DEI PRODOTTI DELLA RICERCA

FERRARINI, Isacco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.764
EU - Europa 2.721
AS - Asia 1.971
SA - Sud America 271
Continente sconosciuto - Info sul continente non disponibili 100
AF - Africa 98
OC - Oceania 21
Totale 7.946
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.680
RU - Federazione Russa 1.200
SG - Singapore 764
IT - Italia 495
CN - Cina 412
GB - Regno Unito 247
VN - Vietnam 231
DE - Germania 220
BR - Brasile 192
HK - Hong Kong 175
BD - Bangladesh 156
FR - Francia 104
FI - Finlandia 103
SE - Svezia 91
IE - Irlanda 88
KR - Corea 53
CA - Canada 45
IN - India 44
NL - Olanda 39
ID - Indonesia 37
PL - Polonia 28
ES - Italia 26
AR - Argentina 25
MX - Messico 23
NG - Nigeria 21
AT - Austria 20
AU - Australia 20
BJ - Benin 19
EC - Ecuador 18
TR - Turchia 18
ZA - Sudafrica 18
JP - Giappone 17
UA - Ucraina 13
IQ - Iraq 12
TG - Togo 10
CL - Cile 9
SA - Arabia Saudita 8
BE - Belgio 7
CO - Colombia 7
MA - Marocco 7
PT - Portogallo 7
CZ - Repubblica Ceca 6
IR - Iran 6
SC - Seychelles 6
DK - Danimarca 5
JM - Giamaica 5
PE - Perù 5
PY - Paraguay 5
TN - Tunisia 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
LT - Lituania 4
PK - Pakistan 4
BO - Bolivia 3
CH - Svizzera 3
IL - Israele 3
KG - Kirghizistan 3
NI - Nicaragua 3
NP - Nepal 3
CG - Congo 2
CR - Costa Rica 2
DZ - Algeria 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
KE - Kenya 2
KW - Kuwait 2
MT - Malta 2
PH - Filippine 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
EE - Estonia 1
EG - Egitto 1
FK - Isole Falkland (Malvinas) 1
GT - Guatemala 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
LS - Lesotho 1
LV - Lettonia 1
LY - Libia 1
MN - Mongolia 1
MU - Mauritius 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
SN - Senegal 1
Totale 7.847
Salva come PNG Salva come JPEG
Città #
Dallas 444
Moscow 432
Singapore 424
San Jose 374
Ashburn 366
Hong Kong 172
Chandler 165
Verona 152
Southend 133
Munich 121
Beijing 108
New York 99
Dublin 82
Council Bluffs 80
Ho Chi Minh City 76
Los Angeles 74
Helsinki 69
The Dalles 60
Hanoi 44
Jacksonville 44
Santa Clara 44
Buffalo 37
Milan 37
London 33
Princeton 29
Lawrence 28
Rome 26
São Paulo 26
Woodbridge 26
Jakarta 25
Orem 25
Warsaw 25
Columbus 21
Houston 20
Jinan 20
Bologna 19
Cotonou 19
Tianjin 19
Wilmington 19
Frankfurt am Main 16
Nanjing 16
Redondo Beach 16
Toronto 16
Ann Arbor 15
Brooklyn 15
Redmond 15
Seattle 15
Abuja 14
Amsterdam 13
Chennai 13
Lappeenranta 13
Melbourne 13
Shenyang 13
Sindelfingen 13
Tokyo 13
Denver 12
Phoenix 12
Vienna 12
Zhengzhou 12
Falkenstein 11
Haiphong 11
Stockholm 11
Turku 11
Changsha 10
Johannesburg 10
Lomé 10
Montreal 10
Nuremberg 10
San Francisco 10
Stuttgart 10
Ankara 9
Belfast 9
Dong Ket 9
Fairfield 9
Seoul 9
Atlanta 8
Chicago 8
Guangzhou 8
Hebei 8
Rio de Janeiro 8
Vicenza 8
Biên Hòa 7
Guayaquil 7
Hangzhou 7
Lagos 7
Padua 7
Trento 7
Vancouver 7
Brussels 6
Charlotte 6
City of London 6
Da Nang 6
Florence 6
Madrid 6
Mahé 6
Manchester 6
Mexico City 6
Paris 6
Querétaro 6
Redwood City 6
Totale 4.622
Salva come PNG Salva come JPEG
Nome #
T CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA: CLINICO-PATHOLOGICAL FEATURES AND RESPONSE TO IMMUNE CHECKPOINT INHIBITORS 283
B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression 233
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 218
Erectile Dysfunction after Allogeneic Hematopoietic Stem Cell Transplant: Results from a Single Center Experience 217
Chronic graft versus host disease is associated with erectile dysfunction in allogeneic hematopoietic stem cell transplant patients: a single-center experience 213
CXCL12 and [N33A]CXCL12 in 5637 and HeLa Cells: Regulating HER1 Phosphorylation via Calmodulin/Calcineurin 213
Synthetic PGI-2 (Iloprost) treatment in patients with resistant sclerodermic chronic GVHD (cGVHD) after Allogeneic Hematopoietic Stem Cell Transplantation 198
Activation of Protein Tyrosine Phosphatase Receptor Type γ Suppresses Mechanisms of Adhesion and Survival in Chronic Lymphocytic Leukemia Cells 195
CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase 192
BID and the α-bisabolol-triggered cell death program: converging on mitochondria and lysosomes 191
A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level 183
Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis 176
Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol α-bisabolol, a dual proapoptotic and antiautophagic agent 174
Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice 166
Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study 164
Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study 163
Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter's syndrome 163
Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment 162
COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review 160
Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis 157
Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40 155
Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia 152
Monocyte-to-macrophage switch reversibly impaired by Ibrutinib. 152
Pembrolizumab as salvage treatment for T-cell/histiocyte-rich and Epstein-Barr virus-positive large B-cell lymphoma 147
CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic Leukemia 140
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 136
Successful rechallenge with azacytidine and venetoclax after sustained treatment-free remission in a relapsed acute myeloid leukemia patient: a case report 134
ONC201 and imipridones: Anti-cancer compounds with clinical efficacy. 130
IMMUNE THROMBOCYTOPENIA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: CASE REPORT AND BRIEF OVERVIEW OF TREATMENT STRATEGIES 127
An updated portrait of monocyte-macrophages in classical Hodgkin lymphoma 124
Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome 122
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 122
West Nile Virus Encephalitis in Haematological Setting: Report of Two Cases and a Brief Review of the Literature 119
CAT RS1001179 SINGLE NUCLEOTIDE POLYMORPHISM IDENTIFIES AN AGGRESSIVE CLINICAL BEHAVIOR IN CHRONIC LYMPHOCYTIC LEUKEMIA 116
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy 115
ONC212 IS A NOVEL MITOCAN ACTING SYNERGISTICALLY WITH GLYCOLYSIS INHIBITION IN PANCREATIC CANCER 111
High prevalence of antibodies reacting to mimotopes of Simian virus 40 large T antigen, the oncoprotein, in serum samples of patients affected by non-Hodgkin lymphoma 110
Extracellular Vesicles based STAT3 delivery as innovative therapeutic approach to restore STAT3 signaling deficiency 109
The mitochondrial anti-apoptotic dependencies of hematologic malignancies: from disease biology to advances in precision medicine 104
CATALASE BLOCKING INDUCES APOPTOSIS AND POTENTIATES VENETOCLAX-INDUCED CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 104
A brisk peripheral T-cell reaction following rituximab treatment for follicular lymphoma 97
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 93
BCR signaling activity stratifies patents with MCL with divergent clinical outcome 89
B-CELL RECEPTOR SIGNALING ACTIVITY IDENTIFIES PATIENTS WITH MANTLE CELL LYMPHOMA AT HIGHER RISK OF PROGRESSION 88
The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment 88
PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF THE B-CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA 86
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 85
Monocyte-to-platelets ratio (MPR) at diagnosis is associated with inferior progression-free survival in patients with mantle cell lymphoma: a multi-center real-life survey 85
ACTIVATION OF BCR SIGNALING REWIRES THE RESPONSE OF BCR-ASSOCIATED KINASES TO IBRUTINIB IN MANTLE CELL LYMPHOMA CELLS 81
ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer 81
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 77
Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients 76
Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma 72
The Importance of Real-World Data in Evaluating the Safety of Biosimilars: A Descriptive Study of Clinical Practice in an Oncohematological Italian Population 71
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia 71
Outcomes of younger patients with mantle‐cell lymphoma experiencing late relapse (>24 months): the LATE‐POD study 70
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper 66
First-line treatment of Waldenström's macroglobulinemia in Italy: A multicenter real-life study on 547 patients to evaluate the long-term efficacy and tolerability of different chemoimmunotherapy strategies 62
THE PROGNOSTIC SIGNIFICANCE OF MYC AND BCL2 PROTEIN DOUBLE EXPRESSION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA, NOS, IN THE ABSENCE OF MYC REARRANGEMENT 60
Zanubrutinib in Hairy Cell Leukemia Variant: Clinical Report and Overview of BTK Inhibition in Variant Disease 27
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy 22
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study 11
No lymphocytosis increase after cBTKi is a rare phenomenon except for CD49d positive CLL mainly expressed in trisomy 12 9
Renal dysfunction in symptomatic Waldenström macroglobulinaemia: A nationwide Italian multicentre study 9
Serositis as possible manifestation in MDS/AML patients with complex karyotype and TP53 mutation: case series 6
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice 5
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 5
Genes-first and phenotypes-first paths to treatment resistance in hematological malignancies 3
Ibrutinib or non-BTK inhibitor therapy in relapsed Waldenström macroglobulinemia: a real-life multicenter Italian study 1
Totale 7.946
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.961
article - articoli 24.434
book - libri 0
conference - conferenze 1.889
curatela - curatele 0
other - altro 638
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022207 0 50 2 10 35 4 7 12 4 14 12 57
2022/2023500 30 67 37 92 38 112 11 36 57 6 7 7
2023/2024327 11 30 49 34 25 41 20 26 9 20 49 13
2024/20251.268 46 49 72 180 55 84 84 86 184 83 124 221
2025/20264.966 216 393 290 632 1.302 279 377 276 377 236 243 345
2026/2027158 113 45 0 0 0 0 0 0 0 0 0 0
Totale 7.946